

## INTERIM FORMULARY UPDATE

The following recommendations, made at the October 10, 2014 meeting of the Executive Formulary Committee, are approved:

Product(s) **approved to be added** to the DADS/DSHS Drug Formulary based on New Drug Applications:  
The Committee did not receive any new drug applications.

Product(s) **deleted** from the DADS/DSHS Drug Formulary:  
No drugs were being considered for deletion at this time.

Other **Recommendation(s)/addition(s)/revisions(s)** to the tables listed in the DADS/DSHS Drug Formulary

Changes made to the Psychotropic Consent List:

- Added vortioxetine (Brintellix®) non-formulary to the Antidepressant section
- Deleted chloral hydrate (Noctec®) from the Anxiolytics/Sedatives/Hypnotics section as it is no longer available
- Added Abilify® Discmelt to the aripiprazole listing under the Antipsychotic section
- Added Versacloz® to the clozapine listing under Antipsychotics
- Added Focalin® XR to the dexamethylphenidate listing under the Stimulant section
- Added methylphenidate solution (Quillivant® XR) to the Stimulant section
- Added prazosin (Minipress®) to the Miscellaneous Drugs section

With the addition of clozapine suspension to the Formulary at the previous meeting, the Committee recommended that the Antipsychotic Tier Schedule be updated. The following changes were made to the Antipsychotic Tier Schedule:

- Increase the relative cost for aripiprazole to 8 dollar signs
- Increase the relative cost of asenapine to 5 dollar signs
- Increase the relative cost of fluphenazine decanoate LAI to 2 dollar signs
- Increase the relative cost of lurasidone to 8 dollar signs
- Increase the relative cost of perphenazine to 3 dollar signs
- Decrease the relative cost of quetiapine to 1 cent sign
- Increase the relative cost of thiothixene to 1 dollar sign
- Change the clozapine listing to “Clozapine Tablets, Oral Disintegrating Tablets”
- Change the relative cost of clozapine tablets to a range of 2 dollar signs to 7 dollar signs to reflect the difference in costs between tablets and oral disintegrating tablets
- Increase the relative cost of iloperidone to 11 dollar signs
- Increase the relative cost of paliperidone to 10 dollar signs
- Increase the relative cost of paliperidone palmitate LAI to 11 dollar signs
- Increase the relative cost of risperidone microspheres LAI to 10 dollar signs
- Decrease the relative cost of ziprasidone to 1 dollar sign
- Add clozapine suspension to the Tier 3 listing with the relative cost of 15 dollar signs
- Increase the relative cost of quetiapine ER to 7 dollar signs
- Increase the relative cost of thioridazine to 2 dollar signs

Separate the “Nasal” section from the “Mouth/Throat” section.  
Delete “Lubricants” section and place that entry in the “Miscellaneous Ophthalmics” section.

Approved:

*Ann Richards, Pharm.D*

---

Ann Richards, Pharm., D., BCPP  
Pharmacy Services Director  
San Antonio State Hospital